Phase 2 trial: the study that started it all The Phase 2 trial, published in the New England Journal of Medicine under the title "Triple Hormone Receptor Agonist Retatrutide for Obesity," is the foundation upon which the entire Phase 3 program was built
Epigallocatechin3gallate (EGCG) from green tea suppresses MAPK, EGFR, and PI3K/Akt pathways, inducing apoptosis and reducing radiationinduced dermatitis in clinical studies
The 3 best sites for GLP-1 injections The FDA has approved three spots on the body where tirzepatide and semaglutide injections are safe and effective: the abdomen, thigh, or upper arm
There are no live phone or video visits
Dosing errors are the most commonly reported issue
A notable research effort, known as the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trial, revealed that participants taking Semaglutide GLP-1 achieved an average weight reduction of around 15% of their starting body weight within 68 weeks, unlike those taking a placebo